CM
TXMD icon

Crestline Management’s TherapeuticsMD TXMD Stock Holding History

Crestline Management’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-1,429
Closed -$486K – 195
2016
Q3 		$486K Buy
+1,429
New +$522K 0.06% 145

Other funds holding TXMD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Crestline Management's TXMD Position: Q4 2016 in Review

Crestline Management sold out of TherapeuticsMD (TXMD) in Q4 2016, closing a stake of 1,429 shares — an estimated $486K sold.

Crestline Management first reported a position in TXMD in Q3 2016 and held it in 1 quarter. The position peaked at $486K in Q3 2016. 146 funds tracked by Wall St. Rank hold TXMD as of Q4 2016.

  • Crestline Management reported no remaining TherapeuticsMD position as of Q4 2016 after selling out during the quarter.
  • Crestline Management sold 1,429 TherapeuticsMD shares in Q4 2016, an estimated $486K.
  • Crestline Management first reported a position in TherapeuticsMD in Q3 2016 and held it in 1 quarter.
  • Crestline Management's TherapeuticsMD position peaked at $486K in Q3 2016.
  • 146 funds tracked by Wall St. Rank held TherapeuticsMD as of Q4 2016.

Based on Crestline Management's 13F filing for Q4 2016, filed 14 Feb 2017.